Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 65 articles:
HTML format
Text format



Single Articles


    July 2018
  1. JACOBS BM, Ammoscato F, Giovannoni G, Baker D, et al
    Cladribine: mechanisms and mysteries in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 10. pii: jnnp-2017-317411.
    PubMed     Text format     Abstract available


  2. LANDI D, Ragonese P, Prosperini L, Nociti V, et al
    Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.
    PubMed     Text format     Abstract available


    June 2018
  3. CHEN J, Taylor BV, Blizzard L, Simpson S Jr, et al
    Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318228.
    PubMed     Text format     Abstract available


    May 2018
  4. TAYLOR BV
    Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
    J Neurol Neurosurg Psychiatry. 2018 May 15. pii: jnnp-2018-318326.
    PubMed     Text format    


  5. RATHBONE E, Durant L, Kinsella J, Parker AR, et al
    Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947.
    PubMed     Text format     Abstract available


    April 2018
  6. CERQUEIRA JJ, Compston DAS, Geraldes R, Rosa MM, et al
    Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2018 Apr 4. pii: jnnp-2017-317509.
    PubMed     Text format    


    March 2018
  7. WIJNANDS JMA, Zhu F, Kingwell E, Fisk JD, et al
    Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493.
    PubMed     Text format     Abstract available


  8. POTTGEN J, Moss-Morris R, Wendebourg JM, Feddersen L, et al
    Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Mar 16. pii: jnnp-2017-317463.
    PubMed     Text format     Abstract available


    December 2017
  9. PATTI F
    Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Dec 23. pii: jnnp-2017-317380.
    PubMed     Text format    


  10. STURNER KH, Stellmann JP, Dorr J, Paul F, et al
    A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
    J Neurol Neurosurg Psychiatry. 2017 Dec 16. pii: jnnp-2017-317101.
    PubMed     Text format     Abstract available


  11. COCOZZA S, Petracca M, Mormina E, Buyukturkoglu K, et al
    Cerebellar lobule atrophy and disability in progressive MS.
    J Neurol Neurosurg Psychiatry. 2017;88:1065-1072.
    PubMed     Text format     Abstract available


    October 2017
  12. AZARY S, Schreiner T, Graves J, Waldman A, et al
    Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-315936.
    PubMed     Text format     Abstract available


  13. FITZGERALD K
    Diet and disease modification in multiple sclerosis: a nutritional epidemiology perspective.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-316375.
    PubMed     Text format    


  14. MEIJER KA, Eijlers AJC, Geurts JJG, Schoonheim MM, et al
    Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 6. pii: jnnp-2017-316329.
    PubMed     Text format     Abstract available


    September 2017
  15. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed     Text format    


  16. PATERGNANI S, Castellazzi M, Bonora M, Marchi S, et al
    Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals.
    J Neurol Neurosurg Psychiatry. 2017 Sep 2. pii: jnnp-2017-316234.
    PubMed     Text format    


    August 2017
  17. SPENCER JI, Bell JS, DeLuca GC
    Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
    J Neurol Neurosurg Psychiatry. 2017 Aug 31. pii: jnnp-2017-316011.
    PubMed     Text format     Abstract available


  18. CALABRESE M, Pitteri M, Farina G, Bajrami A, et al
    Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    J Neurol Neurosurg Psychiatry. 2017 Aug 26. pii: jnnp-2017-316236.
    PubMed     Text format     Abstract available


  19. CLAFLIN SB, van der Mei IAF, Taylor BV
    Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.
    J Neurol Neurosurg Psychiatry. 2017 Aug 2. pii: jnnp-2016-314490.
    PubMed     Text format     Abstract available


  20. KOCH-HENRIKSEN N, Laursen B, Stenager E, Magyari M, et al
    Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
    J Neurol Neurosurg Psychiatry. 2017;88:626-631.
    PubMed     Text format     Abstract available


  21. GRYTTEN N
    Survival in multiple sclerosis: things have changed.
    J Neurol Neurosurg Psychiatry. 2017;88:618.
    PubMed     Text format    


  22. LASCANO AM, Lalive PH, Hardmeier M, Fuhr P, et al
    Clinical evoked potentials in neurology: a review of techniques and indications.
    J Neurol Neurosurg Psychiatry. 2017;88:688-696.
    PubMed     Text format     Abstract available


    July 2017
  23. ZHOU Y, Graves JS, Simpson S Jr, Charlesworth JC, et al
    Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 24. pii: jnnp-2017-315971.
    PubMed     Text format     Abstract available


  24. PREZIOSA P, Rocca MA, Mesaros S, Meani A, et al
    Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
    J Neurol Neurosurg Psychiatry. 2017 Jul 19. pii: jnnp-2017-315863.
    PubMed     Text format    


  25. EISELE P, Szabo K, Alonso A, Ong M, et al
    Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 14. pii: jnnp-2017-316102.
    PubMed     Text format    


    May 2017
  26. TETTEY P, Simpson S, Taylor B, Ponsonby AL, et al
    An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2017;88:395-401.
    PubMed     Text format     Abstract available


    April 2017
  27. RAGONESE P
    Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.
    J Neurol Neurosurg Psychiatry. 2017 Apr 28. pii: jnnp-2017-315591.
    PubMed     Text format    


  28. OKADA K, Kobata M, Sennari Y, Iwanaka Y, et al
    Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Apr 26. pii: jnnp-2017-315585.
    PubMed     Text format    


  29. LUNDE HB, Assmus J, Kjell-Morten M, Bo L, et al
    Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
    J Neurol Neurosurg Psychiatry. 2017 Apr 1. pii: jnnp-2016-315238.
    PubMed     Text format     Abstract available


  30. COMI G, De Stefano N, Freedman MS, Barkhof F, et al
    Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    J Neurol Neurosurg Psychiatry. 2017;88:285-294.
    PubMed     Text format     Abstract available


    March 2017
  31. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Text format     Abstract available


  32. ZALEWSKI NL, Morris PP, Weinshenker BG, Lucchinetti CF, et al
    Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2017;88:218-225.
    PubMed     Text format     Abstract available


    February 2017
  33. JURYNCZYK M, Tackley G, Kong Y, Geraldes R, et al
    Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    J Neurol Neurosurg Psychiatry. 2017;88:132-136.
    PubMed     Text format     Abstract available


    December 2016
  34. ROCCA MA, Filippi M
    Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 30. pii: jnnp-2016-315195.
    PubMed     Text format    


  35. HULST HE, Goldschmidt T, Nitsche MA, de Wit SJ, et al
    rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 14. pii: jnnp-2016-314224.
    PubMed     Text format     Abstract available


    November 2016
  36. TAO C, Simpson S Jr, van der Mei I, Blizzard L, et al
    Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Nov 3. pii: jnnp-2016-314013.
    PubMed     Text format     Abstract available


    October 2016
  37. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Oct 27. pii: jnnp-2016-313867.
    PubMed     Text format     Abstract available


    September 2016
  38. LIZAK N, Lugaresi A, Alroughani R, Lechner-Scott J, et al
    Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976.
    PubMed     Text format     Abstract available


  39. KAWACHI I, Lassmann H
    Neurodegeneration in multiple sclerosis and neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2016 Sep 26. pii: jnnp-2016-313300.
    PubMed     Text format     Abstract available


  40. PARDINI M, Sudre CH, Prados F, Yaldizli O, et al
    Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 6. pii: jnnp-2016-313979.
    PubMed     Text format     Abstract available


    August 2016
  41. PAN G, Simpson S Jr, van der Mei I, Charlesworth JC, et al
    Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
    J Neurol Neurosurg Psychiatry. 2016 Aug 24. pii: jnnp-2016-313722.
    PubMed     Text format     Abstract available


    June 2016
  42. FAREZ MF
    Salt intake in multiple sclerosis: friend or foe?
    J Neurol Neurosurg Psychiatry. 2016 Jun 27. pii: jnnp-2016-313768.
    PubMed     Text format    


  43. NOURBAKHSH B, Graves J, Casper TC, Lulu S, et al
    Dietary salt intake and time to relapse in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Jun 24. pii: jnnp-2016-313410.
    PubMed     Text format     Abstract available


  44. SIMPSON A, Pereira M, Cooper S, Ramagopalan SV, et al
    Seasonality of tweets related to multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Jun 8. pii: jnnp-2016-313941.
    PubMed     Text format    


    May 2016
  45. PATTI F, Messina S, Solaro C, Amato MP, et al
    Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
    J Neurol Neurosurg Psychiatry. 2016 May 9. pii: jnnp-2015-312591.
    PubMed     Text format     Abstract available


    April 2016
  46. MOCCIA M, Palladino R, Falco A, Sacca F, et al
    Google Trends: new evidence for seasonality of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Apr 15. pii: jnnp-2016-313260.
    PubMed     Text format    


  47. WANG C, Beadnall HN, Hatton SN, Bader G, et al
    Automated brain volumetrics in multiple sclerosis: a step closer to clinical application.
    J Neurol Neurosurg Psychiatry. 2016 Apr 12. pii: jnnp-2015-312304.
    PubMed     Text format     Abstract available


    March 2016
  48. WIJNANDS JM, Kingwell E
    Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Mar 3. pii: jnnp-2015-312431.
    PubMed     Text format    


  49. HEDSTROM AK, Mowry EM, Gianfrancesco MA, Shao X, et al
    High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
    J Neurol Neurosurg Psychiatry. 2016 Mar 3. pii: jnnp-2015-312176.
    PubMed     Text format     Abstract available


    February 2016
  50. ZHOVTIS RYERSON L, Frohman TC, Foley J, Kister I, et al
    Extended interval dosing of natalizumab in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Feb 25. pii: jnnp-2015-312940.
    PubMed     Text format     Abstract available


  51. MCGUIGAN C, Craner M, Guadagno J, Kapoor R, et al
    Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
    J Neurol Neurosurg Psychiatry. 2016;87:117-25.
    PubMed     Text format     Abstract available


  52. DISANTO G, Adiutori R, Dobson R, Martinelli V, et al
    Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
    J Neurol Neurosurg Psychiatry. 2016;87:126-9.
    PubMed     Text format     Abstract available


  53. HOEPNER R, Klotz P, Faissner S, Schneider R, et al
    Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis.
    J Neurol Neurosurg Psychiatry. 2016;87:224-6.
    PubMed     Text format    


    December 2015
  54. DOGONOWSKI AM, Blinkenberg M, Paulson OB, Sellebjerg F, et al
    Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2015 Dec 14. pii: jnnp-2015-311375.
    PubMed     Text format    


    October 2015
  55. MASUDA S, Mori M, Arai K, Uzawa A, et al
    Epstein-Barr virus persistence and reactivation in neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2015;86:1137-42.
    PubMed     Text format     Abstract available


    September 2015
  56. HEIDENREICH F
    Long-term treatment of relapsing-remitting multiple sclerosis with interferon beta: how strongly should we encourage patients to adhere to the 'old' therapies?
    J Neurol Neurosurg Psychiatry. 2015 Sep 16. pii: jnnp-2015-310763.
    PubMed     Text format    


  57. KAPPOS L, Kuhle J, Multanen J, Kremenchutzky M, et al
    Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
    J Neurol Neurosurg Psychiatry. 2015 Sep 15. pii: jnnp-2014-310024.
    PubMed     Text format     Abstract available


    August 2015
  58. SETHI V, Yousry T, Muhlert N, Tozer DJ, et al
    A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2015 Aug 13. pii: jnnp-2015-311102.
    PubMed     Text format     Abstract available


  59. MORI M
    Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?
    J Neurol Neurosurg Psychiatry. 2015;86:823.
    PubMed     Text format    


    July 2015
  60. WATTJES MP, Vennegoor A, Steenwijk MD, de Vos M, et al
    MRI pattern in asymptomatic natalizumab-associated PML.
    J Neurol Neurosurg Psychiatry. 2015;86:793-8.
    PubMed     Text format     Abstract available


    June 2015
  61. COHEN JA, Khatri B, Barkhof F, Comi G, et al
    Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
    J Neurol Neurosurg Psychiatry. 2015 Jun 25. pii: jnnp-2015-310597.
    PubMed     Text format     Abstract available


  62. KOCH MW, Greenfield J, Javizian O, Deighton S, et al
    The natural history of early versus late disability accumulation in primary progressive MS.
    J Neurol Neurosurg Psychiatry. 2015;86:615-21.
    PubMed     Text format     Abstract available


    April 2015
  63. ABSOUD M, Lim MJ, Appleton R, Jacob A, et al
    Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
    J Neurol Neurosurg Psychiatry. 2015;86:470-2.
    PubMed     Text format     Abstract available


    March 2015
  64. BAUMANN M, Sahin K, Lechner C, Hennes EM, et al
    Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.
    J Neurol Neurosurg Psychiatry. 2015;86:265-72.
    PubMed     Text format     Abstract available


  65. LALIVE PH, Bridel C, Ferfoglia RI, Kaiser L, et al
    Minimal supportive treatment in natalizumab-related PML in a MS patient.
    J Neurol Neurosurg Psychiatry. 2015;86:354-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: